The MITEF Spain Jury has reached this decision considering their business model, technology, market potential and evolution, and the team itself.
They have developed a technology that is capable of sequencing RNA, from a small blood sample, and associating the expression of genes in more than 320 metabolic pathways that act as biomarkers of the parameters of the individual’s body, analyzing all those variations that are out of the ordinary to improve and prevent health problems.
This project was born as a result of the doctoral thesis, defended at the UPC, of the researcher Emma Roca, a biochemist and elite ultra-distance runner. Roca wanted to analyze the impact of high intensity sport on the runners of an ultra-Trail together with Dr. Jose Manuel Soria, principal investigator of the Genomics of Complex Diseases Research Group of the IIB Sant Pau – Fundació Institut de Recerca Hospital de Sant Pau – Centre CERCA and Dr. Alexandre Perera, physicist, expert in Artificial Intelligence and director of the CREB|UPC, in charge of developing the algorithms that allow the expression of metabolic pathways to be automatically evaluated. Finally, within the framework of the Collider program, in the 2019 edition, Dr. Teresa Tarragó, CEO of the project, and Pol Cervera, director of operations, joined in to give the business perspective and face the market.
Congratulations to the whole Exheus Team! Awesome work!